Egalet A/S, a Danish company that has developed technology for the controlled release of drugs through gradual erosion of a tablet, said it has appointed Peter Nordkild as chief executive officer, replacing Jan Quistgaard.
Mr Nordkild was previously chief commercial officer of Pharmexa A/S, a Danish company which is developing active immunotherapy and vaccines for the treatment of cancer.
Last month, Egalet appointed Bertrand Damour, formerly co-head of investment banking and risk management at J.P. Morgan in London, as its chief financial officer.
Source:
1. Personal communication, Egalet press officer, 27 August 2007
Copyright 2007 Evernow Publishing Ltd